FLUOCINOLONE ACETONIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (1963)
Entry Type: Small molecule
Molecule Category: Parent
ATC: C05AA10
UNII: 0CD5FD6S2M

Structure
InChI Key FEBLZLNTKCEFIT-VSXGLTOVSA-N
Smile CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
InChI
InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H30F2O6
Molecular Weight 452.49
AlogP 2.37
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 2.0
Polar Surface Area 93.06
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 32.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Glucocorticoid receptor agonist
Primary Target
Glucocorticoid receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - -
Enzyme Transferase
- - - - 11.26
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 1
- 3.131 - 1.423 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 3
- 26 - 3.346 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Melanosis 4 D008548 ClinicalTrials
Uveitis, Anterior 3 D014606 ClinicalTrials
Uveitis, Intermediate 3 D015867 ClinicalTrials
Uveitis, Posterior 3 D015866 ClinicalTrials
Macular Degeneration 2 D008268 ClinicalTrials
Retinal Diseases 2 D012164 ClinicalTrials
Macular Degeneration 2 D008268 ClinicalTrials
Glaucoma 1 D005901 ClinicalTrials

Related Entries

MCS

Scaffolds

Mixture
Mixture
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Eye disorders
20.68
Skin and subcutaneous tissue disorders
14.4
General disorders and administration site conditions
12.93
Injury, poisoning and procedural complications
12.37
Surgical and medical procedures
7.94
Nervous system disorders
7.2
Product issues
6.56
Investigations
5.26
Immune system disorders
2.22
Vascular disorders
2.12

Cross References

Resources Reference
CAS NUMBER 67-73-2
ChEBI 31623
ChEMBL CHEMBL989
DrugBank DB00591
DrugCentral 1204
EPA CompTox DTXSID0040674
FDA SRS 0CD5FD6S2M
Human Metabolome Database HMDB14729
Guide to Pharmacology 7077
PharmGKB PA164754912
PubChem 6215
SureChEMBL SCHEMBL4795
ZINC ZINC000003977981
CONTENTS